The most common tirzepatide side effects are nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, burping, decreased appetite, tiredness, and reactions where you inject the medicine
For individuals with a body mass index (BMI) of 30 kg/m or above (or 27.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds), NICE recommends considering pharmacological interventions alongside lifestyle changes when dietary and exercise modifications alone have been insufficient
Natural GLP-1 cannot be used therapeutically because it is rapidly degraded by the enzyme DPP-4 within 1-2 minutes, requiring continuous intravenous infusion for sustained effect
Inhibition of non-CYP enzymes especially UDP-glucuronosyltransferases (UGTs) significantly predicts high risk for drug-induced liver injury (DILI)